- Home
- BHLB vs CLDX Comparison
BHLB vs CLDX Comparison
Compare BHLB & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHLB
- CLDX
- Stock Information
- Founded
- BHLB 1846
- CLDX N/A
- Country
- BHLB United States
- CLDX United States
- Employees
- BHLB N/A
- CLDX N/A
- Industry
- BHLB Banks
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BHLB Finance
- CLDX Health Care
- Exchange
- BHLB Nasdaq
- CLDX Nasdaq
- Market Cap
- BHLB 1.1B
- CLDX 1.3B
- IPO Year
- BHLB 2000
- CLDX 2008
- Fundamental
- Price
- BHLB $26.62
- CLDX $22.59
- Analyst Decision
- BHLB Buy
- CLDX Strong Buy
- Analyst Count
- BHLB 4
- CLDX 9
- Target Price
- BHLB $33.88
- CLDX $46.13
- AVG Volume (30 Days)
- BHLB 383.9K
- CLDX 1.3M
- Earning Date
- BHLB 07-24-2025
- CLDX 08-07-2025
- Dividend Yield
- BHLB 2.84%
- CLDX N/A
- EPS Growth
- BHLB 404.16
- CLDX N/A
- EPS
- BHLB 2.56
- CLDX N/A
- Revenue
- BHLB $438,910,000.00
- CLDX $5,790,000.00
- Revenue This Year
- BHLB $30.73
- CLDX N/A
- Revenue Next Year
- BHLB $79.15
- CLDX N/A
- P/E Ratio
- BHLB $9.91
- CLDX N/A
- Revenue Growth
- BHLB 35.24
- CLDX N/A
- 52 Week Low
- BHLB $22.27
- CLDX $14.40
- 52 Week High
- BHLB $32.36
- CLDX $47.00
- Technical
- Relative Strength Index (RSI)
- BHLB 53.67
- CLDX 47.91
- Support Level
- BHLB $25.20
- CLDX $20.37
- Resistance Level
- BHLB $25.61
- CLDX $25.65
- Average True Range (ATR)
- BHLB 0.44
- CLDX 1.50
- MACD
- BHLB 0.09
- CLDX -0.14
- Stochastic Oscillator
- BHLB 74.67
- CLDX 39.37
About BHLB Berkshire Hills Bancorp Inc.
Berkshire Hills Bancorp Inc is a holding company. It provides Commercial Banking, Retail Banking, Consumer Lending, Private Banking and Wealth Management services.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.